Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) has announced the appointment of two oncologists, Michael Smylie and Jonathan Trites, to its scientific advisory board to support its ongoing clinical and research initiatives.
Dr Smylie is a medical oncologist at the Cross Cancer Institute in Edmonton and a clinical professor at the University of Alberta.
He is known for his work in melanoma research, including his involvement in the CheckMate 067 clinical trial. The study examined the effects of combination immunotherapy treatments for advanced melanoma and contributed to evolving standards of care, particularly in improving long-term survival outcomes.
Dr Trites is a head and neck oncologic and reconstructive surgeon based at the Queen Elizabeth II Health Sciences Centre in Halifax and serves as an associate professor at Dalhousie University.
His research has focused on surgical approaches for head and neck cancers, including the use of minimally invasive techniques. His published work includes findings on transoral laser microsurgery as a treatment option for certain advanced-stage cancers, as well as studies on various forms of squamous cell carcinoma.
Sona’s chief medical officer, Dr Carman Giacomantonio, said the two physicians bring significant clinical and research experience that will inform the company’s future clinical direction.
“The clinical course we are embarking upon is truly pioneering. Both Dr Trites and Dr Smylie have been pioneers throughout their careers in their respective fields, giving me and my team a tremendous amount confidence as we plan and begin to execute our clinical course going forward,” Giacomantonio said.